MAR – Page 3 – Alligator Bioscience

2023-05-11

Regulatory

Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement

Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...

2023-03-222023-03-29

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-01-02

Regulatory

52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...

2023-01-02

Regulatory

The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...

2021-11-29

Regulatory

rights issue of shares (the “Rights Issue”) ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubs ...

2021-10-07

Regulatory

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has today, subject to approval by th ...

2021-09-02

Regulatory

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...

2021-08-18

Regulatory

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...

2021-06-04

Regulatory

Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...